Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Myopathic Mitochondrial DNA Depletion Syndrome Press Release / May 31, 2022June 3, 2024
Stealth BioTherapeutics Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022 Press Release / May 23, 2022June 3, 2024
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy Press Release / May 12, 2022June 3, 2024
Stealth Biotherapeutics Announces Data from ReCLAIM-2 Phase 2 Trial of Elamipretide in Geographic Atrophy Press Release / May 2, 2022June 3, 2024
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich’s Ataxia Press Release / March 28, 2022June 3, 2024
Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented at ARVO (2022) Press Release / March 24, 2022June 3, 2024
Stealth BioTherapeutics to Host Virtual Event on the Potential of Elamipretide in Treatment of Geographic Atrophy in Dry Age-Related Macular Degeneration Press Release / March 17, 2022June 3, 2024
Stealth BioTherapeutics Showcases New Duchenne Muscular Dystrophy Nonclinical Data at the 2022 Muscular Dystrophy Association and Clinical Scientific Conference Press Release / March 16, 2022June 3, 2024
Stealth BioTherapeutics to Present at Mitochondria-Targeted Drug Development Summit Press Release / February 22, 2022June 3, 2024
Last Patient Completes Treatment in Stealth BioTherapeutics’ Phase 2 Geographic Atrophy Clinical Trial Press Release / February 15, 2022June 3, 2024
